Decoding biology to radically improve lives
Recursion Pharmaceuticals is focused on the intersection of imaging and Artificial Intelligence to find new ways to use drugs to treat rare genetic diseases. The technology platform can be expanded to identify potential targets or therapeutics for any disease that can be modeled in human cells, including in the areas of inflammation, infectious disease, aging and diagnostics. IPO (NASDAQ: RXRX): April 16, 2021.
Combining AI, automation, and synthetic biology to evolve next-generation protein therapeutics